000156003 001__ 156003
000156003 005__ 20240328115555.0
000156003 0247_ $$2doi$$a10.3390/pharmaceutics13030379
000156003 0247_ $$2pmid$$apmid:33809385
000156003 0247_ $$2pmc$$apmc:PMC7999378
000156003 0247_ $$2altmetric$$aaltmetric:102431678
000156003 037__ $$aDZNE-2021-01135
000156003 041__ $$aEnglish
000156003 082__ $$a610
000156003 1001_ $$00000-0001-5846-7058$$aScuteri, Damiana$$b0
000156003 245__ $$aDevelopment and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocumarins, in the Control of Agitation in Severe Dementia.
000156003 260__ $$aBasel$$bMDPI$$c2021
000156003 3367_ $$2DRIVER$$aarticle
000156003 3367_ $$2DataCite$$aOutput Types/Journal article
000156003 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711616219_27787
000156003 3367_ $$2BibTeX$$aARTICLE
000156003 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156003 3367_ $$00$$2EndNote$$aJournal Article
000156003 520__ $$aDementia is one of the most common causes of disability worldwide characterized by memory loss, cognitive impairment, and behavioral and psychological symptoms (BPSD), including agitation. Treatment of the latter consists of the off-label use of harmful atypical antipsychotics, though a significant reduction is afforded by pain control. The use of an essential oil endowed with analgesic properties and devoid of toxicity would represent an important option for the management of agitation in dementia. Therefore, the aim of this study was to engineer a nanotechnology delivery system based on solid lipid nanoparticles loaded with bergamot essential oil (BEO) and devised in the pharmaceutical form of an odorless cream (NanoBEO) to confirm its analgesic efficacy for further development and application to control agitation in dementia. BEO has proven strong antinociceptive and anti-allodynic properties and, in its bergapten-free form, it is completely devoid of phototoxicity. NanoBEO has been studied in vivo confirming the previously reported analgesic activity of BEO to which is now added its anti-itching properties. Due to the nanotechnology delivery system, the stability of titrated BEO components is guaranteed. Finally, the latter invention, currently under patent consideration, is smell-devoid allowing efficacy and safety to be established in double-blind clinical trials; until now the latter studies have been impeded in aromatherapy by the strong odor of essential oils. A clinical trial NCT04321889 has been designed to provide information about the efficacy and safety of NanoBEO on agitation and pain in patients suffering from severe dementia.
000156003 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000156003 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000156003 650_7 $$2Other$$aBPSD
000156003 650_7 $$2Other$$aagitation
000156003 650_7 $$2Other$$adementia
000156003 650_7 $$2Other$$aessential oil of bergamot
000156003 650_7 $$2Other$$ananotechnology delivery system
000156003 650_7 $$2Other$$apain
000156003 7001_ $$00000-0001-6980-6799$$aCassano, Roberta$$b1
000156003 7001_ $$aTrombino, Sonia$$b2
000156003 7001_ $$00000-0001-8758-6523$$aRusso, Rossella$$b3
000156003 7001_ $$aMizoguchi, Hirokazu$$b4
000156003 7001_ $$aWatanabe, Chizuko$$b5
000156003 7001_ $$00000-0001-9146-8554$$aHamamura, Kengo$$b6
000156003 7001_ $$aKatsuyama, Soh$$b7
000156003 7001_ $$aKomatsu, Takaaki$$b8
000156003 7001_ $$aMorrone, Luigi Antonio$$b9
000156003 7001_ $$00000-0002-1727-3158$$aRombolà, Laura$$b10
000156003 7001_ $$00000-0003-1869-2642$$aAdornetto, Annagrazia$$b11
000156003 7001_ $$aLaganà, Annarita S$$b12
000156003 7001_ $$00000-0001-6472-0697$$aCorasaniti, Maria Tiziana$$b13
000156003 7001_ $$aTonin, Paolo$$b14
000156003 7001_ $$aSakurada, Shinobu$$b15
000156003 7001_ $$aSakurada, Tsukasa$$b16
000156003 7001_ $$0P:(DE-2719)2010732$$aNicotera, Pierluigi$$b17$$udzne
000156003 7001_ $$00000-0001-8540-6218$$aBagetta, Giacinto$$b18
000156003 770__ $$aLipid Nanoparticles in the Treatment of Neurological and Other Aging Related Disorders
000156003 773__ $$0PERI:(DE-600)2527217-2$$a10.3390/pharmaceutics13030379$$gVol. 13, no. 3, p. 379 -$$n3$$p379$$tPharmaceutics$$v13$$x1999-4923$$y2021
000156003 8564_ $$uhttps://pub.dzne.de/record/156003/files/DZNE-2021-01135.pdf$$yOpenAccess
000156003 8564_ $$uhttps://pub.dzne.de/record/156003/files/DZNE-2021-01135.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000156003 909CO $$ooai:pub.dzne.de:156003$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000156003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2010732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000156003 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000156003 9141_ $$y2021
000156003 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000156003 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000156003 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000156003 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICS : 2021$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-08-24T11:04:26Z
000156003 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000156003 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-08-24T11:04:26Z
000156003 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000156003 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000156003 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bPHARMACEUTICS : 2021$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000156003 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000156003 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000156003 9201_ $$0I:(DE-2719)5000018$$kAG Nicotera$$lSynaptic Connectivity and Neurodegeneration$$x0
000156003 980__ $$ajournal
000156003 980__ $$aVDB
000156003 980__ $$aUNRESTRICTED
000156003 980__ $$aI:(DE-2719)5000018
000156003 9801_ $$aFullTexts